Current trends in management of the beta thalassemias

Indian Pediatrics

Volumn 36, Issue 12, 1999, Pages 1229-1242

  Shah, Dheeraj ^a   Choudhury, Panna ^a,b   Dubey, A P ^a  

^a LOK NAYAK HOSPITAL   (India)

^b DII/M 2753 ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN F; VITAMIN;

BETA THALASSEMIA; BLOOD TRANSFUSION; BONE DISEASE; BONE MARROW TRANSPLANTATION; DIET; GENE THERAPY; HEMOGLOBIN SYNTHESIS; HUMAN; IRON CHELATION; PERIPHERAL BLOOD STEM CELL; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION;

BETA-THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHELATING AGENTS; DEFEROXAMINE; HUMANS;

EID: 0033461816     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Weatherall DJ, Clegg JB. Thalassemia-a global public health problem. Nat Med 1996; 2: 847-849.
2. Olivieri NF. The B-Thalassemias. N Engl J Med 1999; 341: 99-109.
3. Marwah RK, Lal A. Present status of hemoglobinopathies in India. Indian Pediatr 1994;31:267-271.
4. Management Protocol for Treatment of Thalassemia Patients. Cyprus, Thalassemia International Federation, 1997.
5. Cao A, Galanello R, Rosatelli MC, Argiolu F, Virgilils SD. Clinical experience of management of thalassemia: the Sardinian experience. Semin Hematol 1996;33:66-75.
6. Olivieri NF, Nathan DG, Macmillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta thalassemia. N Engl J Med 1994; 331: 574-578.
7. Olivieri NF, Brittenham GM. Iron chelating therapy and treatment of thalassemia. Blood 1997; 89: 739-761.
8. Kumar RM, Riak DE, Khurana A. Beta thalassemia major and successful pregnancy. J Reprod Med 1997; 42: 294-298.
9. Sirchia G, Wenz B, Rebulla P. Removal of white cells from red cells by transfusion through a new filter. Transfusion 1990; 30: 30-33.
10. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42: 81-85.
11. Angelucci E, Giardini C, Brittenham GM Lucarelli G. Hepatic iron concentrations and body iron stores determined by quantitative phlebotomy in patients cured of thalassemia major by bone marrow transplantation. Blood 1997; 90: (Suppl 1): 265 a. abstract.
12. Olivieri NF, Brittenham GM. Iron chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761 [Erratum, Blood 1997, 89: 2621].
13. Brittenham GM, Farrel DE, Harris JW. Magnetic susceptibility measurements of human iron stores. N Engl J Med 1982; 307: 1671-1675.
14. Mazza P, Gida R, De Moxo S, Bonetti MS, Amerri B, Magi C. Iron overload in thalassemia: Comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Hematologica 1995; 80: 398-404.
15. Brittenham GM, Griffith PM, Nienhaus AW, Mclaren CE, Tucker EE, Alen CJ, et al. Efficacy of desferrioxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573.
16. Lucarelli G, Giardini C, Baronciani D. Bone marrow transplantation in thalassemia. Semin Hematol 1995; 32: 297-303.
17. Sharma BK, Choudhury P, Dubey AP. Desferrioxamine: It's use in iron chelation in thalassemia. Indian Pediatr 1990; 27: 314-319.
18. Borgna PC, Cohen A. Evaluation of a new method of administration of the iron chelating agent desferrioxamine. J Pediatr 1997; 130: 86-88.
19. Aggarwal MB. Living with Thalassemia. Bombay, Bhalani Book Depot, 1986.
20. Kontoghiorges GJ, Aldouri MP, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al. Effective chelation of iron in thalassemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. BMJ 1987; 295: 1509-1512.
21. Agarwal MB, Gupte SS, Vishwanathan C, Vasandani D, Ramanathan J, Desai N, et al. Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassemia: Indian trial. Br J Hematol 1992; 82: 460-466.
22. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan, Olivieri, NF, Tondury. P, et al. Results of long term deferiprone (L1) therapy: A report by the International Study Group on oral iron chelators. Br J Hematol 1995: 91: 224-229.
23. Olivieri NF. Thalassemia today. Acta Hematologica 1998; 100 (Suppl 1): 9.
24. Piga A, Longo I, Voi V, Facello S, Tartaglia N. Advances in iron chelating therapy. Acta Hematologica 1998; 100 (Suppl 1): 270.
25. Williams DN, Kaur B. Postsplenectomy care: Strategies to decrease the risk of infection. Postgrad Med J 1996; 100: 195-205.
26. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High prevalence of low bone mass in thalassemia major. Br J Hematol 1998; 103: 911-915.
27. Filosa A, Di Maio S, Vocca S, Saviano A, Esopotito G, Pagono L. Longitudinal monitoring of bone mineral density in thalassemia patients: Genetic structure and osteoporosis. Acata Pediatr 1997; 86: 342-346.
28. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, et al. Short stature and failure of pubertal development in thalassemia major: Evidence hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotrophin secretion. Eur J Pediatr 1997; 156: 777-783.
29. Filosa A, Di Maio S, Saviano A, Vocca S, Esposito G. Can adrenarche influence the degree of osteopenia in thalassemic children? J Pediatr Endocrinol Metab 1996; 9: 401-406.
30. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Ahi G, Gamberini MR, et al. Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996; 155: 368-372.
31. Pafuni C, Roccasalva L, Pernicone G, Spano G, Palumbo MA, Gregorio FD, et al. Osteopenia in female beta-thalassemic patients. J Pediatr Endocrinol metab 1998; 11: 989-991.
32. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 1998; 11: 795-801.
33. Singer ST, Vichinsky EP. Bone disease in beta thalassemia (Commentary). Lancet 1999; 354: 881-882.
34. DeAlarcan PA, Donovan ME, Foebes GB, Landau SA, Stockam JA. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med 1979; 300: 5-8.
35. Disler PB, Lynch SR, Charton RW, Torrance JD, Bothwell TH, Walker RB, et al. The effect of lea on iron absorption. Gut 1975; 16: 193-200.
36. Singh J, Mangal NK, Khinchi YR. Diet in regularly transfused thalassemics. Indian Pediatr 1994; 30: 1453-1456.
37. Thomas ED, Buckner CD, Sanders JE. Marrow transplantation for thalassemia. Lancet 1982; 2: 227-229.
38. Lucarelli G, Clift RA, Galinberti M, Polchi P, Angelucci E, Baronciani D, et al. Marrow transplantation for patients with thalassemia: Results in class 3 patients. Blood 1996; 87: 2062-2088.
39. Piomelli S. Cooley's anemia management: 25 years of progress. In: Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches. Eds. Buener CD, Gale RP, Lucarelli G. New York, Alan R Liss, 1989; pp 23-26.
40. Chandy M. Bone marrow transplantation for thalassemia. In: Proceedings of 2nd National Thalassemia Conference. New Delhi, 1997; pp 61-66.
41. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417-421.
42. Giardnini C, Lucarelli G, Galinberti M, Baronciani D, Angelico E, Polchi P, et al. Bone marrow transplantation in thalassemia. Acta Hematologica 1998; 100 (Suppl 1): 284.
43. Mehra NK. Asian Indian Donor Marrow Registry. In: Proceedings of 2nd National thalassemia Conference 1997, New Delhi, 1997; 58-60.
44. Ossenkoppele GJ, Jonkoff AR, Huihgens PC, Nauta JJP, Vander HKG, Drager AM. Peripheral blood progenitor cells mobilized by G-CSF (Filgrastim) and rein fused as unprocessed autologous whole blood shorten the pancytopenic period following high dose melphalan in multiple myeloma. Bone marrow Transplant 1994; 13: 37-41.
45. Choudhry VP. Hematopoictic Stem cell transplantation. Indian Pediatr 1997; 34: 505-517.
46. Silberstein LE, Jefferies LC. Placental blood banking. A new frontier in transfusion medicine. N Engl J Med 1996; 335: 199-201.
47. Kurteber J, Laughlin M, Graham ML, Smith C, Olsan JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cell for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-166.
48. Westgren M, Ringden O, Eik-Nes S, Ek S, Anvret M, Brubakk AM, et al. Lack of evidence of permanent engraftment aller in utero fetal stem cell transplantation in congenital hemoglobinopathies. Transplantation 1996; 61: 1176-1179.
49. Leboutch P, Huang GS, Humphires RK. Mutagenesis of retroviral vectors transducing beta globin gene and beta globin locus control regioti derivates results in stable transmission of an active transcriptional structures. EMBO J 1994; 13: 3065-3076.
50. Beuzard Y. Towards gene therapy of hemoglobinopathies. Semin Hematol 1996; 33: 43-52.
51. Harrington SJ, Van Bokklen G, Mays RW. Formation of de novo centromeres and construction of first generation human artificial microsomes. Nature Genetics 1997; 4: 345-355.
52. Loqnnou PD, Amemiya CT, Garnes J, Kroisel PM, Shizuya H, Chen C, et al. A new bacteriophage P1 desired vector for the propagation of large human DNA fragments. Nature Genetics 1994; 6: 84-89.
53. Rivella S, Sadelain M. Genetic treatment of severe hemoglobinopathies: The combat against transgene variegation and transgenic silencing. Semin Hematol 1998; 35: 112-125.
54. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta J, Witkowska HE, et al. A short term trial of butyrate to stimulate fetal globin gene expression in the beta-globin disorders. N Engl J Med 1993; 328: 129-131.
55. Faller DV, Perrie SP. Butyrates in the treatment of sickle cell disease and beta thalassemia, Curr Opin Hematol 1995; 2: 109-117.
56. Choudhry VP, Lal A, Pati HP, Arya LS. Hematological responses to hydroxyurea therapy in multi transfused thalassemic children. Indian J Pediatr 1997; 64: 395-398.
57. Arruda VR, Lima CSP, Saad STO, Costa FF. Successful use of hydroxyurea in B-thalassemia major. New Engl J Med 1997; 336: 964.
58. Olivieri NF, Rees DC, Ginder GD, Thein, Brittenham GM, Waye JS, et al. Treatment of thalassemia major with phenylbutyrate and hydroxyurea. Lancet 1997; 350: 491-492.
59. Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe B-globin disorders. Brit J Hematol 1995; 91: 263-268.
60. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phe-nylbutyrate therapy in homozygous beta thala-ssemia: A clinical trial. Blood 1995; 85: 43-49.
61. Rind D, Fibach E, Goldfar BA, Friedbarg A, Rachmilewitz EA. Heme arginate therapy for beta thalassemia: in vitro versus in vivo effects. Acta Hematol 1998; 100: 82-84.
62. Rachmilewitz EA, Goldfarls A, Dover G, Administration of erythropoietin to patients with beta thalassemia intermedia: A preliminary trial. Blood 1991; 78: 1145-1147.
63. Olivieri NF, Freedman M, Perrine S, Dover GJ, Sheridan B, Essentine DL, et al. Trial of recombinant human erythropoietin in thalassemia intermedia. Blood 1992; 80: 3258-3260.
64. Maheswari M, Arora S, Kabra M, Menon PSN. Carrier screening and prenatal diagnosis of β-thalassemia. Indian Pediatr 1999; 36: 1119-1125.